COVID-19：Fujifilm与VLP Therapeutics签订合同：疫苗的合同生产
-使用药物输送系统技术进行合同制造-
VLP治疗学：
我们向日本的国家研发公司AMED /公开发售的疫苗开发（第二次公开发售）申请了疫苗。
2020年8月，VLP Therapeutics的下一代COVID-19疫苗的开发被采纳为研发议程。
下一代疫苗的开发：
国家国际医学研究中心，
医药基础设施，健康与营养研究所，
与大分大学和大阪市立大学
我们计划共同开发下一代COVID-19疫苗。
富士胶卷[日本]
https://www.fujifilm.com/jp/ja/news/list/5493
Fujifilm Concludes a Manufacturing Contract Agreement with VLP Therapeutics,
for a COVID-19 Vaccine Formulation
TOKYO, October 1, 2020—
FUJIFILM Corporation
has announced the conclusion of a manufacturing contract agreement with biotechnology company VLP Therapeutics Japan LLC regarding a COVID-19 vaccine formulation developed by VLP Therapeutics.
VLP Therapeutics’ COVID-19 vaccine
is a self-amplifying (replicon) RNA*1vaccine that uses a formulation (lipid nanoparticle)*2, which is a type of Drug Delivery System (DDS) technology*3.
Fujifilm
will utilize its manufacturing facilities and infrastructure for lipid nanoparticle to handle operations relating to VLP Therapeutics’ COVID-19 vaccine formulations, from process development to manufacturing for clinical trials.
VLP Therapeutics is the Japanese subsidiary of VLP Therapeutics, LLC, a U.S. biotechnology company engaged in the development of next-generation COVID-19 vaccines, aiming to prevent infections for which no effective treatment methods exist.
Research
is currently under way at VLP Therapeutics LLC to produce next-generation COVID-19 vaccines that can, by using replicons, demonstrate a high amount of efficacy even with inoculation in small amounts, reduce the risk of adverse reactions, and cope with some genetic mutation.